Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
This publication presents a clinical study evaluating the efficacy and safety of a novel targeted therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring specific genetic mutations.
The trial demonstrated:
- Significant improvement in progression-free survival
- Higher overall response rate compared to standard treatment
- Manageable safety profile
These findings support the use of this targeted agent as a new standard of care in this molecularly defined NSCLC population.